Adolescent migraine

Lewis D, Ashwal S, Hershey A, et al. Practice parameter Pharmacological treatment of migraine headache in children and adolescents. Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004 63 2215-2224. 

The selective serotonin reuptake inhibitors (SSRI) have been used in adults for a wide variety of disorders, including major depression, social anxiety (social phobia), generalized anxiety disorder (GAD), eating disorders, premenstrual dysphoric disorder (PMDD), post-traumatic stress disorder (PTSD), panic, obsessive-compulsive disorder (OCD), trichotillomania, and migraine headaches. Some of the specific SSRI agents have an approved indication in adults for some of these disorders, as reviewed later in this chapter. The SSRIs have also been tried in children and in adults for symptomatic treatment of pain syndromes, aggressive or irritable ( short fuse ) behavior, and for self-injurious and repetitive behaviors. This chapter will review general aspects of the SSRIs and discuss their approved indications in children and adolescents. 

The experience was safe and effective. We approximated the dosage at bOug. LSD. I speculated that the migraines were caused by adolescent neuroses. The medication kept the migraines at bay, once every few weeks in a variety of environments. Then there was no more LSD available, my friend Yota moved, kids were selling d-Con and scopolomine in capsules as mescaline or acid or what ever you wanted it be. 

Psychological In a randomized, doubleblind, placebo-controlled, multicenter study of the prevention of attacks of migraine, 103 adolescents (aged 12 through 17 years) were randomized to topiramate 50 mg/day... 

Divalproex sodium extended-release has been evaluated in a 12-month, open extension of a 3-month, double-blind, placebo-controlled, multicenter study in 112 adolescents with migraine [339. The most common symptomatic adverse events were weight gain (15%), nausea (14%), somnolence (12%), upper respiratory tract infection (11%), and sinusitis (8%). Five subjects had serious adverse events, and 15 prematurely withdrew because of an adverse event. Plasma ammonia concentrations were increased in 8% but there were no other clinically significant changes in laboratory values, vital signs, or electrocardiography. 

Apostol G, Pakalnis A, Laforet GA, Robieson WZ, Olson E, Abi-Saab WM, Saltarelli M. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches results of an open-label extension trial in adolescents. Headache 2009 49(1) 36-44. 

---